NCT06396637View on ClinicalTrials.gov

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
DRUG

Sapropterin Dihydrochloride

Sapropterin Dihydrochloride: 20mg/kg, qd

Trial Locations (1)

510060

RECRUITING

Cancer center of Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER

NCT06396637 - PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC | Biotech Hunter | Biotech Hunter